We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





AACC: Better Quality and Patient-Friendliness Needed in Direct Testing

By LabMedica International staff writers
Posted on 27 Jul 2015
Print article
In a new position statement on direct-to-consumer (DTC) laboratory testing, the American Association for Clinical Chemistry (AACC; Washington DC, USA) emphasizes the need for patient-friendly reports and for sufficient transparency about quality of tests and results.

DTC testing allows people to order medical tests directly from a lab, without going through their healthcare provider. Noting the paradigm shift among consumers seeking greater control over their own healthcare, AACC has issued a position statement that emphasizes DTC test results must be accurate and easily understood—an area where laboratory medicine professionals play a vital role.

State laws have limited to physicians the ordering of lab tests, but as people have become more engaged in managing their own healthcare, this model has begun to change. Currently, 37 states and the District of Columbia permit consumers to order some or all of their laboratory tests without involvement of a physician. Individuals can also buy over-the-counter test kits or get laboratory services from non-traditional settings such as retail centers. These DTC lab tests can provide invaluable information to individuals about their health status in a timely and convenient manner. However, many healthcare providers and policymakers are concerned that some of these tests may be of questionable quality and value, or that consumers might not have enough background knowledge to make sound decisions based on their test results.

To enhance patient benefit, AACC urges the Centers for Medicare and Medicaid Services and the US Food and Drug Administration (FDA) to require that DTC testing providers disclose sufficient information about their products and services, enabling consumers to make well-informed decisions. These providers should provide: user-friendly descriptions of risks, benefits, and limitations of all tests offered; clear and understandable reports of test results, with enough information to assist in decision-making; prominent instructions to contact a qualified healthcare provider with any questions or concerns; and a comprehensive, public listing of tests offered and prices charged.

Laboratory medicine professionals are integral to this consumer-driven process. AACC encourages lab professionals to collaborate with federal agencies to inform the public about the costs, benefits, interpretation, and limitations of DTC tests. Likewise, consumers should consult qualified professionals in making decisions about their healthcare.

“DTC laboratory testing is a key element of ongoing efforts to empower people in decisions affecting their healthcare,” said AACC CEO Janet B. Kreizman, “AACC supports expanding consumer access to high-quality DTC testing services, and urges policymakers to ensure that these services have demonstrated clinical validity and utility and make a positive impact on patient outcomes.”

Related Links:

American Association for Clinical Chemistry (AACC)
AACC position statement on direct-to-consumer testing


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.